Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Strong Sell

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Sell

Standard Deviation

Neutral

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Sell

C

Redhill Biopharma Ltd. (RDHL)

https://www.redhillbio.com

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

01/07/2013

Market Cap

9,897,888

Shares Outstanding

7,869,850,000

Weighted SO

19,674,633

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

ORGO --.--%

LFCR --.--%

TARO --.--%

COLL --.--%

AQST --.--%

EVOK --.--%

ADMP --.--%

GHSI --.--%

ACRX --.--%

Beta

3.6260

Last Div

0.0000

Range

0.257-3.28

Chg

-0.0644

Avg Vol

6928946

Mkt Cap

9897888

Exch

NASDAQ

Country

IL

Phone

972 3 541 3131

DCF Diff

0.6335

DCF

1.6535

Div Yield

0.0000

P/S

1.8346

EV Multiple

0.0456

P/FV

0.3527

Div Yield %

0.0000

P/E

0.0240

PEG

0.0061

Payout

0.0000

Current Ratio

0.9595

Quick Ratio

0.7843

Cash Ratio

0.2482

DSO

402.7516

DIO

745.5480

Op Cycle

1148.2996

DPO

469.7601

CCC

678.5395

Gross Margin

0.5518

Op Margin

8.5735

Pretax Margin

9.4536

Net Margin

9.4536

Eff Tax Rate

1.3022

ROA

1.4557

ROE

18.6309

ROCE

6.7524

NI/EBT

1.0000

EBT/EBIT

1.1027

EBIT/Rev

8.5735

Debt Ratio

0.0652

D/E

0.6580

LT Debt/Cap

0.2226

Total Debt/Cap

0.3969

Int Coverage

19.7077

CF/Debt

-7.7824

Equity Multi

10.0942

Rec Turnover

0.9063

Pay Turnover

0.7770

Inv Turnover

0.4896

FA Turnover

2.3935

Asset Turnover

0.1540

OCF/Share

-4.5092

FCF/Share

-4.5110

Cash/Share

1.7793

OCF/Sales

-3.2947

FCF/OCF

1.0004

CF Coverage

-7.7824

ST Coverage

-13.7791

CapEx Coverage

-2539.2857

Div&CapEx Cov

-2539.2857

P/BV

0.3527

P/B

0.3527

P/S

1.8346

P/E

0.0240

P/FCF

-0.5566

P/OCF

-0.0689

P/CF

-0.0689

PEG

0.0061

P/S

1.8346

EV Multiple

0.0456

P/FV

0.3527

DPS

0.0000

Latest Headlines (EST)

MarketWatch Dec 01, 07:06 Bill Gross says beaten-down mortgage plays may thrive — and offer huge yields MarketWatch Nov 30, 09:33 These advisers say markets are expecting unrealistic outcomes. Here are some alternatives. MarketWatch Nov 29, 08:41 Bill Ackman warns economy will fall off a cliff if the Fed doesn’t hurry and cut rates Benzinga Nov 27, 13:41 Why Anavex Life Sciences Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Revenue Product Segmentation